Literature DB >> 8751193

The low positive rate of serum alpha-fetoprotein levels in hepatitis C virus antibody-positive patients with hepatocellular carcinoma.

J Furui1, M Furukawa, T Kanematsu.   

Abstract

We analyzed the clinicopathological factors influencing the serum AFP levels at the time of diagnosis in 114 patients with resected HCC. The proportion of HCC patients with high serum AFP levels (> 100 ng/ml) has been steadily decreasing from a rate of 57.2% in 1980 to 33.3% in 1993. A significant relationship was noted between the serum AFP levels and the virus marker (p < 0.01) based on a multivariate analysis. The proportion of HCC patients with high serum AFP levels was significantly less in anti-HCV- positive HCC patients than in HBsAg-positive HCC patients (p < 0.01). The proportion of HBsAg-positive HCC patients has been steadily decreasing from a rate of 48% in 1980 to 15% in 1993. In contrast, the proportion of anti-HCV-positive HCC patients was 69% in 1993. It is thus assumed that the prevalence of anti-HCV-positive HCC patients is increasing recently, based on the fact that the incidence of HCC patients with high serum AFP levels is decreasing.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8751193

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

1.  The Plasma and Serum Metabotyping of Hepatocellular Carcinoma in a Nigerian and Egyptian Cohort using Proton Nuclear Magnetic Resonance Spectroscopy.

Authors:  Mohamed I F Shariff; Jin Un Kim; Nimzing G Ladep; Asmaa I Gomaa; Mary M E Crossey; Edith Okeke; Edmund Banwat; Imam Waked; I Jane Cox; Roger Williams; Elaine Holmes; Simon D Taylor-Robinson
Journal:  J Clin Exp Hepatol       Date:  2017-03-15

2.  HCC with low- and normal-serum alpha-fetoprotein levels.

Authors:  Brian I Carr; Hikmet Akkiz; Oguz Üsküdar; Kendal Yalçın; Vito Guerra; Sedef Kuran; Ümit Karaoğullarından; Engin Altıntaş; Ayşegül Özakyol; Salih Tokmak; Tuğsan Ballı; Mehmet Yücesoy; Halil İbrahim Bahçeci; Abdulalh Ülkü; Tolga Akçam; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necati Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Ali Demir; Anıl Delik; Burcu Arslan; Figen Doran; Sezai Yilmaz; Yaman Tokat
Journal:  Clin Pract (Lond)       Date:  2018

3.  Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review.

Authors:  Ryosuke Tateishi; Haruhiko Yoshida; Yutaka Matsuyama; Norio Mine; Yuji Kondo; Masao Omata
Journal:  Hepatol Int       Date:  2007-12-29       Impact factor: 6.047

4.  The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia.

Authors:  Chyntia Olivia Maurine Jasirwan; Alessa Fahira; Lianda Siregar; Imelda Loho
Journal:  BMC Gastroenterol       Date:  2020-07-09       Impact factor: 3.067

Review 5.  Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?

Authors:  Senthil Rajappa; Kun-Ming Rau; Palanki Satya Dattatreya; Anant Ramaswamy; Philana Fernandes; Aarohan Pruthi; Rebecca Cheng; Mariusz Lukanowski; Yi-Hsiang Huang
Journal:  World J Hepatol       Date:  2022-06-27

6.  Antibody Arrays Identify Potential Diagnostic Markers of Hepatocellular Carcinoma.

Authors:  Hongbo Sun; Mei-Sze Chua; Dorothy Yang; Anya Tsalenko; Brian J Peter; Samuel So
Journal:  Biomark Insights       Date:  2008-01-21

7.  Relatively Long Survival in Hepatocellular Carcinoma Presenting With Carcinoid Syndrome.

Authors:  Sylvester Chuks Nwokediuko; Ijoma Uchenna; Ofoegbu Esther; Okafor Okechukwu; Onuh Augustine; Ajuyah Charity
Journal:  Gastroenterology Res       Date:  2010-01-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.